CONTEXT: Presentation at the European Hematology Association (EHA) 2021 Virtual Congress of a post-approval safety study on Truxima (biosimiliar rituximab) in patients with large B-cell lymphoma. Results showed similar results to reference rituximab from patients across Europe. The findings are expected to assist in evidence-based decisions on cost-effective treatments for patients.
IMPACT: Low
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 8
1. “The majority of IRRs were grade 1 or 2 (96%), with the most common IRR being fatigue (35% n=7/20 of the patients with index IRRs), followed by nausea (30% n=6/20) and vomiting (15% n=3/20). ”
2. “Celltrion Healthcare presents the first real-world data for Truxima® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress. ”
3. “Of the 382 patients observed, over three quarters initiated on CT-P10 achieved complete or partial response by 30 months, with 82% having recorded a complete response (n=312). ”
4. “Of DLBCL patients, 30-40% are thought to relapse and 10% of patients have refractory disease. ”
5. “Truxima is the first rituximab similar biotherapeutic product to be prequalified by the World Health Organization (May 2020). ”